Artificial intelligence may soon play a critical role in choosing which depression therapy is best for patients.
A national trial initiated by UT Southwestern in 2011 to better understand mood disorders has produced what scientists are calling the project’s flagship finding: a computer that can accurately predict whether an antidepressant will work based on a patient’s brain activity.
The new research is the latest among several studies from the trial that cumulatively show how high-tech strategies can help doctors objectively diagnose and prescribe depression treatments. Although implementing these approaches will take time, researchers predict tools such as AI, brain imaging, and blood tests will revolutionize the field of psychiatry in the coming years.
“These studies have been a bigger success than anyone on our team could have imagined,” says Madhukar Trivedi, M.D., a UT Southwestern psychiatrist who oversaw the multi-site trial involving Stanford, Harvard and other institutions. “We provided abundant data to show we can move past the guessing game of choosing depression treatments and alter the mindset of how the disease should be diagnosed and treated.”
The study published in Nature Biotechnology included more than 300 participants with depression who were randomly chosen to receive either a placebo or an SSRI (selective serotonin reuptake inhibitor), the most common class of antidepressant. Researchers used an electroencephalogram, or EEG, to measure electrical activity in the participants’ cortex before they began treatment. The team then developed a machine-learning algorithm to analyze and use the EEG data to predict which patients would benefit from the medication within two months.
Not only did the AI accurately predict outcomes, further research suggested that patients who were doubtful to respond to an antidepressant were likely to improve with other interventions such as psychotherapy or brain stimulation.
The findings were validated in three additional patient groups.
“This study takes previous research, showing that we can predict who benefits from an antidepressant, and actually brings it to the point of practical utility,” says Amit Etkin, M.D., Ph.D., a Stanford University psychiatry professor who worked with Trivedi to develop the algorithm.
Among the next steps, researchers say, is developing an AI interface that can be widely integrated with EEGs across the country, as well as seeking approval from the U.S. Food and Drug Administration.
Signatures of depression
Data from the study derive from the 16-week EMBARC trial, which Trivedi initiated at four U.S. sites to establish biology-based, objective strategies to remedy mood disorders.
The project evaluated patients with major depressive disorder through brain imaging and various DNA, blood, and other tests. His goal was to address a troubling finding from another study he led (STAR*D) that found up to two-thirds of patients do not adequately respond to their first antidepressant.
“We went into this thinking, ‘Wouldn’t it be better to identify at the beginning of treatment which treatments would be best for which patients?'” Trivedi explains.
Previous EMBARC studies identified various predictive tests, including the use of magnetic resonance imaging (MRI) to examine brain activity in both a resting state and during the processing of emotions. EEG will likely be the most commonly used tool, Trivedi says, because it’s less expensive and – in most cases – will be equally or more effective.
However, a blood test or MRI may be needed for some patients if the depression is manifesting itself in a different way.
“There are many signatures of depression in the body,” Trivedi says. “Having all these tests available will improve the chances of choosing the right treatment the first time.”
According to data from the National Health and Nutrition Examination Survey, antidepressant use in the U.S. has increased nearly 65% over a decade and a half – from 7.7% in 1999-2002 to 12.7% in 2011-2014. Trivedi says the expanded use of medications makes it more critical to further understand the underpinnings of depression and ensure patients are prescribed an effective therapy.
While his team continues to evaluate data from the EMBARC trial, Trivedi has initiated other large research projects to help improve the remission rate of depression. Among them is D2K, a study that will enroll 2,500 patients with depression and bipolar disorders and follow them for 20 years. In addition, RAD is a 10-year study of 2,500 participants (ages 10-24) that will uncover factors for reducing the risk of developing mood or anxiety disorders.
Utilizing some of these enrollees, Trivedi’s research team will study the results from several other tests to assess patients’ biological signatures to determine the most effective treatment.
“It can be devastating for a patient when an antidepressant doesn’t work,” Trivedi says. “Our research is showing that they no longer have to endure the painful process of trial and error.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Trusted support may help teens battle depressionon March 3, 2021 at 10:51 pm
Learning about their health through a trusted source may help teens take better care of themselves, leading to less depressive symptoms, says a new study.
- 'I was pretty much in a depression': A Brewers pitcher had trouble moving past his nightmarish playoff outingon March 3, 2021 at 5:57 pm
Brewers lefty Brent Suter said the support of family, friends and fans helped him recover from giving up two runs in 1⅔ innings against the Dodgers.
- Learning about health from trusted sources may help teens battle depressionon March 3, 2021 at 12:41 pm
Depression can be a common problem for teens and adolescents, and while many treatments exist, they don't always work for everyone. A new study found that feeling more informed about their health may ...
- Suzanne Shaw opens up on 18-year struggle with depression and anxietyon March 3, 2021 at 11:52 am
Suzanne Shaw has said she's "struggled" with depression and anxiety for nearly two decades. The former Hear'Say singer said she has managed to get rid of the "self-loathing" “I’ve struggled with ...
- Peripheral inflammatory biomarkers define biotypes of bipolar depressionon March 3, 2021 at 10:28 am
Higher baseline proinflammatory cytokines mark poor antidepressant response in bipolar disorder. J Clin Psychiatry. 2017;78:e986–93. Arteaga-Henríquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Predicting depression patient outcomes
- Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patientson March 1, 2021 at 8:52 am
Taxanes are used in the treatment of several solid tumours. Adverse events (AEs) might be influenced by single nucleotide polymorphisms (SNPs) in genes encoding proteins responsible for ...
- How to responsibly predict depression diagnoses using social mediaon February 16, 2021 at 4:00 pm
While those lamentable outcomes were measured through ... this kind of analysis might be able to predict future depression, since identifying patients at an earlier stage in their mental illness ...
- Development of an Outcome Prediction Tool for Patients Considering a Total Knee Replacementon February 15, 2021 at 3:59 pm
This study tested the feasibility of the recruitment procedure and the type and presentation of questionnaires used to measure patient factors ... Factors that predict outcome will form part ...
- New Study Favors Myriad Genetics' (MYGN) GeneSight Teston February 10, 2021 at 9:21 am
Further, the study used data from the Genomics Used to Improve DEpression ... testing in predicting variation in medication blood levels. In turn, this may lead to improved patient outcomes.
- Mental Health Startup ReachLink Announces Partnership to Improve Outcomeson February 4, 2021 at 7:38 pm
Many analysts are predicting this trend will ... Eleos expands ReachLink's visibility into outcomes by analyzing data from both the clinician and patient. This insight helps to inform how we ...